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Abstract
Purpose The lethal effects of cancer are associated with
the enhanced tumor aggressiveness in recurrent and meta-
static lesions that show resistant phenotype to anti-cancer
therapy, a major barrier to improving overall survival of
cancer patients. The presence of heterogeneous populations
of cancer cells within a specific tumor including the tumor-
initiating cells or so-called cancer stem cells (CSCs) has
linked the acquired resistance (AR, or adaptive resistance).
Herein, we discuss the CSC-mediated tumor repopulation
in AR of breast cancer in this review.
Methods We emphasize a dynamic feature of gene
induction in tumor cells that undergo long-term treatment,
and describe a specific HER2-NF-jB-HER2 pro-survival
pathway that can be initiated in breast CSCs upon radiation
therapy.
Results Elucidation of HER2-induced pro-survival net-
works, specifically the force driving tumor repopulation
due to radioresistant CSCs during anticancer therapies, will
have a significant impact on the generation of new diag-
nostic and therapeutic targets to control of recurrent and
metastatic breast tumors.
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Abbreviations
AR Acquired resistance
CSCs Cancer stem cells
UPA Urokinase plasminogen activator
ALDH1 Aldehyde dehydrogenase-1
RTKs Receptor tyrosine kinases




PGK1 Phosphoglycerate kinase 1
PTEN Phosphatase and tensin homolog
Ras-MAPK Ras-mitogen-activated protein kinase
MGMT O6-Methylguanine-DNA
methyltransferase
EGFR Epidermal growth factor receptor
SirT1 Silencing information regulator2
homolog
HDAC Histone deacetylase
ATM Ataxia telangiectasia mutated
IKK IjB kinase
NEMO NF-jB essential modulator
SUMO Small ubiquitin-like modifier
SH2 Src homology 2
PTB Phosphotyrosine binding
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PI3 K-PKB/Akt Phosphatidylinositol 30kinase-protein
kinase B
PLC-PKC Phospholipase C-protein kinase C
IHC Immunohistochemistry
FISH Fluorescence in situ hybridization
STAT3 Signal transducer and activator of
transcription 3
Introduction
The recurrence and metastasis of primary tumor cells to
distant organs, particularly to bone, lungs, liver, and brain
following traditional anti-cancer therapy have been the
challenge for successful anti-cancer strategies for breast
cancer (Lacroix 2006). Radiotherapy continues to be a
powerful tool for the control of tumor growth, contributing
to the overall survival rate of the majority of cancer
patients. However, it is well known that tumors develop
adaptive response (AR) to radiation therapy and become
more resistant, aggressive, and invasive (Ahmed and Li
2007). Revealing the insights of the acquired radioresis-
tance in the recurrent and metastatic tumors is essential to
further improve the efficacy of cancer treatment.
Cancer stem cells (CSCs) definition emerged shortly
after the discovery of only a small fraction of tumor cells
being able to form colonies or new tumors (Al-Hajj et al.
2003; Bonnet and Dick 1997). These fractions express
specific cell surface markers that differentiate them from
the rest of the tumor cell populations. The initial stem cell
markers of breast cancer are defined as CD44?/CD24-/low
(Al-Hajj et al. 2003). Cells with these cell surface markers
are shown to have elevated levels of pro-invasive genes
required for metastasis, including interleukins such as IL-
1a, IL-6, IL-8, and urokinase plasminogen activator (UPA)
(Sheridan et al. 2006). However, further studies suggested
that CD44?/CD24-/low feature alone is not enough for the
spread of breast cancer (Sheridan et al. 2006) pointing to
the existence of additional markers to define potential
breast CSCs. In 2007, Ginestier et al. introduced aldehyde
dehydrogenase-1 (ALDH1) as an additional marker for the
breast CSCs, and recently, our laboratory showed that
HER2 is a novel breast CSC marker responsible for their
resistance to radiation therapy (Duru et al. 2012). The
continuous and urgent need to define specific biomarkers to
precisely identify breast CSCs for the early detection of
tumor progression and the prevention of metastasis accel-
erated the research in this area extensively.
Clinical data suggest that breast cancer patients with
tumors overexpressing HER2/neu, a member of ErbB
family of receptor tyrosine kinases (RTKs), live one-third
shorter than the patients with a HER-2/neu negative tumor,
and the enhancement of HER2 copies is also correlated
with the relapsing time of the disease (Arteaga et al. 2012;
Asada et al. 2002; Slamon et al. 1987). We have previously
shown that, upon radiation exposure, HER2 activates a pro-
survival transcription factor, NF-jB, through Akt-mediated
pro-survival pathways (Guo et al. 2004), and interestingly,
HER2, itself, is among the genes that are transcriptionally
activated by NF-jB upon radiation, indicating a positive
feedback loop between HER2 and NF-jB (Cao et al.
2009). Defining the central role of NF-jB in these path-
ways may offer new therapeutic targets for breast cancer
treatment (Ahmed et al. 2006); however, it also increased
the challenge of implementation since NF-jB is currently
involved in the regulation of more than 150 target genes
(Pahl 1999). Therefore, detecting HER2 as both down-
stream and upstream element of NF-jB signaling is
encouraging given that this unique relationship may allow
novel approaches to target HER2 in breast cancer therapy.
In this review, we will discuss recent findings in pro-sur-
vival signaling networks that are critical for the acquired
tumor resistance in breast CSCs.
Tumor adaptive response, CSC-mediated tumor cell
repopulation
Increased tumorigenicity of an identifiable subpopulation
of cancer cells with specific surface markers was first
studied in acute myeloid leukemia (AML), where these
cells were referred to as cancer stem cells (Bonnet and
Dick 1997; Pardal et al. 2003). CSC concept supports a
hierarchical organization of the tumor cells and predicts
that only a specific subset of tumor cells with stem cell-like
properties, such as the capacity to self-renew and generate
the heterogeneous lineages of cancer cells, is able to ini-
tiate tumorigenesis. Several CSC markers have been
reported for a variety of solid tumors including breast,
brain, prostate, pancreas, and colon cancers (Hermann et al.
2007; Hurt et al. 2008; Patrawala et al. 2006; Ricci-Vitiani
et al. 2007; Singh et al. 2004). The finding that only a small
subset in entire tumor cells has this significant self-renewal
potential and the ability to proliferate in an uncontrolled
manner (Al-Hajj 2007; Al-Hajj et al. 2003) challenged the
assumption that the chance of each cancer cell to form a
new tumor is equivalent (O’Brien et al. 2010). These fea-
tures in CSCs render them a hot topic in cancer research,
especially since new evidence emerges frequently to sup-
port their roles in tumor recurrence, aggressiveness, and
therapy resistance, which results in inefficient cancer
treatments (Duru et al. 2012; Gangopadhyay et al. 2013;
McDermott and Wicha 2010).
Radiotherapy has been extensively used for tumor con-
trol via the initiation of DNA damage-induced cell death.
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However, long-term observations of irradiated cells have
revealed that apart from apoptosis, a variety of cell fates
emerge among irradiated cell populations (Forrester et al.
2000; Prieur-Carrillo et al. 2003), suggesting that specific
mechanisms were activated in the surviving heterogenic
population of tumor cells. Therapeutic efficiency of ion-
izing radiation (IR) is associated with IR-induced apoptotic
responses (Almasan 2000; Dewey et al. 1995), genomic
instability (Morgan 2003; Morgan and Murnane 1995),
bystander effects (Klokov et al. 2004; Morgan 2003;
Morgan and Murnane 1995), and adaptive radioresistance
(Ch’ang et al. 2005; McBride et al. 2002). Radioresistance
is also linked with the signaling cascades activated during
temporary but significant cell cycle arrest (Bebien et al.
2003; Fornace et al. 1999; Hartwell and Kastan 1994), the
degree of DNA damage, the activation of signaling net-
works; and the activation of pro-survival or pro-apoptotic
signaling pathways determines the fate of an irradiated cell
(Feinendegen 1999, 2002; Maity et al. 1997; Schmidt-
Ullrich et al. 2000; Stecca and Gerber 1998; Waldman
et al. 1997; Weichselbaum et al. 1994; Wolff 1989, 1998).
The induced protection/tolerance of irradiated cells is also
evident since pre-exposure to a low or intermediate dose of
X- or c-rays reduces the lethal effects and genomic insta-
bility caused by subsequent exposures of higher doses of IR
(Kelsey et al. 1991; Olivieri et al. 1984; Robson et al. 2000;
Skov 1999; Suzuki et al. 1998, 2001). Therefore, a better
understanding of the molecular mechanisms underlying the
tumor adaptive response is necessary to further increase the
efficacy of anti-cancer therapy.
The tumor radioresistance creates a serious challenge to
the current cancer treatments (Stockler et al. 2000), and
CSCs are shown to be more radioresistant than the non-
stem cancer cells, suggesting that the decrease in the tumor
size after radiotherapy results mainly from the sensitivity
of non-CSC cancer cells rather than a previously believed
random tumor cell death (Baumann et al. 2008). In addition
to their resistant phenotype, Al-Hajj et al. (2003) showed
that CSCs are more tumorigenic than non-stem cancer
cells, such that breast cancer cells expressing CD44
(CD44?) but not CD24 (CD24-/low) are more tumorigenic
since as few as 100 cells with this phenotype are able to
form tumors in mice while millions of cells missing this
phenotype are not. This resulted in the identification of
CD44?/CD24-/low as the marker of breast CSCs in 2003
(Al-Hajj et al. 2003). Thereafter, Phillips et al. (2006)
showed that the breast cancer cells expressing CD44?/
CD24-/low are more radioresistant, supporting a notion that
CSCs are more radioresistant than the non-stem cancer
cells and placing CSC research at the core of tumor
adaptive radioresistance studies.
CSCs are believed to be responsible for treatment failure
and tumor recurrence (Al-Hajj et al. 2004; Reya et al.
2001). Repopulation of cancer cells upon anti-cancer
therapies has long been considered as the cause of treat-
ment failure (Kim and Tannock 2005). Dylla et al. (2008)
showed the repopulation and increased tumorigenicity of
colorectal CSCs (CD44?ESA?) in xenogeneic tumors
subsequent to chemotherapy (Dylla et al. 2008). In a recent
paper, Pajonk’s group showed that IR is capable of
reprogramming differentiated breast cancer cells into
induced breast CSCs (iBCSCs). Moreover, iBCSCs dis-
played enhanced mammosphere formation and tumorige-
nicity as well as expressed the same stemness-related genes
as BCSCs from non-irradiated samples. Their study pro-
posed that BCSC phenotype was induced by radiation in
differentiated breast cancer cells, which contributed to the
enrichment of BCSCs after anti-cancer treatments (Laga-
dec et al. 2012). Repopulation of CSCs has also been
supported clinically, such that the percentages of CSCs are
found to be increased following cytotoxic chemotherapy in
breast cancer patients (Diehn et al. 2009). Diehn et al.
(2009) discussed that it is plausible to assume the presence
of different subclones of CSCs with different sets of
mutations/genomic alterations within tumors, since heter-
ogeneous tumors consist of unstable genomes. Upon
chemo- or radio-therapy, the CSC clones with the advan-
tageous genomic alteration to protect against therapy
would be selected for and continue to sustain the tumor
(Diehn et al. 2009). To support this idea, Bao et al. (2006a,
b) reported that glioma cancer stem cells acquired radio-
resistance by promoting DNA damage repair (Bao et al.
2006b). Odoux et al.’s (2008) study supported the existence
of genomic instability in the CSCs showing that the kary-
otypes of parental tumor cells were mostly similar to the
derived clones except some of them had unique chromo-
somal aberrations (Odoux et al. 2008). It is also possible
that during the progress of cancer, anti-cancer therapy
might cause the CSCs to acquire new mutations that might
render CSCs more resistant to therapy as well as helping
them self-renew. This theory might also explain the higher
percentages of CSCs seen in the recurrent tumors (Diehn
et al. 2009). Klonisch et al. concluded that CSCs can
appear as a result of modifications in the microenvironment
of the stem cell niche, as a result of mutations that might
lead to a change in the signaling pathways and cell cycle
control or as a result of enrichment of cell populations with
specific phenotypes (Klonisch et al. 2008). Li and Neaves
(2006) proposed that the differences between normal stem
cells and CSCs are the degree of their dependence on the
specialized microenvironment of stem cells, so-called stem
cell niche, and they discuss that an alteration in the sig-
naling networks governing the homeostatic regulation of
the niche might disrupt the stem cell maintenance. There-
fore, CSCs may arise from an intrinsic mutation leading to
self-sufficient cell proliferation or alteration of the niche by
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proliferation-promoting signals that might become domi-
nant. Liu and Wicha (2010) reinforced the importance of
stem cell niche for the regulation of cellular functions.
They discuss how breast CSCs are governed by the ele-
ments that form stem cell niche, in addition to the intrinsic
signals. Their review brings up the importance of paracrine
interactions in the regulation of cellular functions and
emphasizes that some of these altered interactions are
involved the signaling pathways, which include Wnt,
Notch, and Hedgehog (Liu and Wicha 2010).
These findings shed light onto a new conceptual para-
digm of how breast CSCs or cancer-initiating cells con-
tribute to the radiation response. There are numerous
complicated mechanisms involved in adaptive resistance. It
is realistic to think that radiation-induced mutations in
some tumor cells give survival advantage to the cells and
contribute to their acquired radioresistance. However, it is
also likely that radiation selectively kills the relatively
radiosensitive tumor cell populations leaving the therapy-
resistant CSCs alive, thus contributing to adaptive radio-
resistance via the selective repopulation of CSCs. Our
recent publication showing the repopulation of HER2?
breast CSCs upon radiation treatment provides another
evidence that supports the latter (Duru et al. 2012). Further
studies are necessary to fully understand the exact mech-
anisms of the acquired radioresistance, but the involvement
of selection along with the introduction of mutations seems
crucial. The elucidation of the key features of the adaptive
response is essential for the discovery of specific gene/
protein targets to re-sensitize radioresistant fractions of the
tumor that will ultimately increase the efficacy of anti-
cancer therapy.
DNA repair and the radioresistance of CSCs
One of the common characteristics of normal stem cells
and CSCs is their ability to protect DNA from stress-
induced damage substantially better than the non-stem cells
(Frosina 2009). The average mutation rate in somatic cells
in vivo is 10-4, as opposed to a 10-6 in embryonic stem
cells (Hong et al. 2007), suggesting an enhanced DNA
repair activity in stem cells. Although radiation induces
multitudes of damage in cells, the main mechanism of
radiation-mediated killing is via generating hard-to-repair
DNA damage after apoptosis (Bao et al. 2006a). Under-
standing the detailed mechanisms by which stem cells
retain less DNA damage is crucial for the treatment for
cancers resistant to radio- and chemo-therapy.
Increased ability of CSCs for DNA repair (Johannessen
et al. 2008) accounts for the low rate of apoptosis they
have. Bao et al. (2006a) reported that glioma stem cells are
able to promote radioresistance by enhancing DNA
damage repair and lowering the rate of apoptosis. Their
results indicate the radiation-induced repopulation of
CD133? tumor cells, which are suggested as glioblastoma
CSCs (Liu et al. 2006). CD133? glioma cells survive
radiation by preferentially activating DNA damage
checkpoints and repairing the radiation-induced DNA
damage more effectively than the CD133- glioma cells.
This was supported by the findings that the addition of
inhibitors specific for Chk1 and Chk2 checkpoint kinases
sensitized the radioresistant CD133? glioma cells (Bao
et al. 2006a). Consistent with it, Rich (2007) proposed that
the transient activation of the DNA checkpoints leads to
cell cycle arrest, which is a required step for the initiation
of DNA repair process. Accumulating evidence demon-
strates a relationship between radioresistance and DNA
damage signaling via a variety of mechanisms (Puc et al.
2005; Skvortsova 2008). It is of great value to clarify
whether these mechanisms are predominantly activated in
the CSCs compared to other tumor cell populations.
Skvortsova et al. (2008) suggested that the radioresistance
in prostate carcinoma cells is achieved by the activation of
signaling pathways controlling cell survival and DNA
repair. Phosphoglycerate kinase 1 (PGK1) is one of the
proteins up-regulated in the radioresistant prostate cancer
cell lines, which is known to have roles in both DNA
replication and repair in mammalian cells. Moreover,
PGK1 was identified as a downstream effector of HER2
signaling and contributes to the aggressiveness of the
breast cancer. Another DNA base damage repair protein
up-regulated in radioresistant prostate cancer cells is DNA-
(apurinic or apyrimidinic site) lyase, which is encoded by
the APEX1 gene and normally involved in the repair of pre-
mutagenic lesions. It was shown to mediate DNA damage
repair via the regulation of several transcription factors
including NF-jB (Skvortsova 2008). Induction of NF-jB
has also been associated with the loss of PTEN, a tumor
suppressor gene that negatively regulates Akt signaling
pathway (Chu and Tarnawski 2004). Interestingly, the
induction occurs via PI3K/Akt pathway, suggesting a
positive feedback mechanism, which is suggested to be
involved in the cancer chemoresistance (Gu et al. 2004). In
addition to PI3K/Akt pathway, other signaling pathways
including Ras/MAPK induced by several cytokines, growth
factors, and tyrosine kinases can also activate NF-jB.
NF-jB activation is a transient process that has to be
tightly regulated to avoid overenhancing the survival of the
cells. In tumor cells, dysregulation of different signaling
pathways as well as alterations in the activity or the
expression of several genes may lead to the misregulation
of NF-jB, enabling its constitutive activation. These genes
are involved in cell cycle control, migration, adhesion, and
apoptosis among the NF-jB target genes (Dolcet et al.
2005). Lavon et al. (2007) reported one of the first data
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showing the role of NF-jB in the regulation of DNA repair
mechanisms. O6-methylguanine-DNA methyltransferase
(MGMT) is a DNA repair enzyme, which is responsible for
the resistance of cancer cells to several alkylating agents,
thus conferring chemoresistance to certain tumor types
(Lavon et al. 2007; Margison et al. 2003). The elevated
activity of MGMT has been detected in many types of
tumors including breast cancer, although the levels of
activation were variable and even absent in some tumors
(Margison et al. 2003). In glioma cell lines, the activity of
NF-jB is associated with the expression of MGMT (Lavon
et al. 2007). Further experiments showed that NF-jB is a
major player in the regulation of MGMT, suggesting a new
model for the mechanism of DNA damage repair mediated
by NF-jB upon exposure to alkylating agents (Lavon et al.
2007). Accordingly, it is plausible to suggest a link
between the activation of DNA damage proteins and NF-
jB-HER2-NF-jB feedback loop in radioresistant breast
CSCs. As a matter of fact, the relationship between NF-jB
activity and radioresistance has been shown in MCF7
breast cancer cells (Cao et al. 2009). Further studies are
crucial to demonstrate that this relation is exclusive to
BCSCs and might contribute significantly to their radio-
resistance. Moreover, the conceivable model of Lavon
et al. (2007) points to new targets for developing thera-
peutic strategy to cure chemo-resistant tumors. To support
this, our most recent data further suggest that large sets of
DNA repair proteins were up-regulated in HER2? BCSCs
(Duru et al. 2012). We believe that, in the near future,
studies focusing on the relation between DNA damage
response and therapy resistance in CSCs will result in the
development of new therapeutics against radioresistance.
Pro-survival signaling networks in CSCs
Therapeutic IR causes DNA damage and generates oxida-
tive stress in cells leading to the activation of specific
signaling pathways in the irradiated cells (Spitz et al.
2004). Depending on the extent of DNA damage, either
pro-apoptotic or pro-survival pathways are initiated.
Studies on glioma CSCs revealed the complex regulation
of CSCs. Several signaling pathways including the acti-
vation of RTKs, bone morphogenetic proteins (BMPs),
Hedgehog, and Notch are shown to be important for gov-
erning glioma CSCs. The epidermal growth factor receptor
(EGFR), a member of RTK family, is shown to play a
significant role for the proliferation and neurosphere for-
mation in glioma CSCs. Activation of pro-survival PI3K/
Akt pathway, which is downstream of RTKs, has been
shown to be more dominant in glioma CSCs compared to
non-stem glioma cells. Hedgehog pathway that is also
reported to be active in gliomas has been suggested to be
required for self-renewal of CSCs (Li et al. 2009).
Hambardzumyan et al. (2006) showed the importance of
the activation of PI3K/Akt/mTOR pathway in conferring
radioresistance to subpopulations of medulloblastoma
cells. They showed that at least three different populations
of tumor cells give different responses upon IR. The main
cell population, which was radiosensitive, underwent p53-
dependent apoptosis. The other two populations were
radioresistant, including nestin-expressing stem cells and
non-proliferating cells. The nestin-expressing stem cells
underwent p53-dependent cell cycle arrest, while the non-
proliferating cells did not respond to radiation (Ham-
bardzumyan et al. 2008). Phillips et al. (2006) showed that
Notch signaling pathway is activated in breast CSCs
through PI3 K pathway upon exposure to radiation, which
resulted in increased number of CSCs (Phillips et al. 2006).
Notch1 has been shown to be overexpressed in breast
cancer, and its expression levels have been associated with
breast cancer prognosis. Several genes, including HER2,
CyclinD1, CDK2, and Notch4, are up-regulated via acti-
vation of Notch1 signaling (Phillips et al. 2006). The
importance of Notch pathway in breast cancer stem cells
has been previously shown, and the Notch-binding
sequence was found in HER2 promoter, suggesting a
relationship between Notch and HER2. Moreover, HER2-
overexpressing cells show active Notch signaling (Korkaya
and Wicha 2009). Interestingly, the formation of iBCSCs
and thus the enrichment of BCSCs upon anti-cancer
treatment can be prevented to some extent with the inhi-
bition of Notch signaling pathway, suggesting that target-
ing Notch signaling might be a good treatment strategy
after radiation therapy (Lagadec et al. 2012). Several other
studies also point to the importance of targeting Notch
signaling pathway as an anti-cancer treatment. The role of
Notch1-mediated signaling pathway in maintenance of
neural stem cells, which contributes to growth and pro-
gression of glioblastomas, is essential, and it has been
shown that Notch1 receptor promotes survival of glio-
blastoma cells by regulation of the anti-apoptotic Mcl-1
protein, which is mediated by the induction of EGFR (Fassl
et al. 2012; Wang et al. 2010). Clementz et al. showed that
Notch-1 and Notch-4 are novel targets of PEA3 in breast
cancer cells and suggested that targeting PEA3 and Notch
signaling pathways would provide a new therapeutic
strategy for triple-negative and possibly other breast cancer
subtypes (Clementz et al. 2011). A significant association
between the increased expression of Notch1 and HER2 in
breast cancer suggested that Notch signaling pathway
should be a therapeutic target, especially for HER2-posi-
tive breast cancers with poor prognosis (Zardawi et al.
2010).
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NF-jB initiated pro-survival networks
NF-jB-mediated pro-survival pathway is one of the major
signaling pathways activated by DNA damage (Ahmed and
Li 2008). NF-jB is a sequence-specific transcription factor
originally involved in inflammation and carcinogenesis
(Baldwin 1996; Karin 2006). In typical/canonical pathway,
the components of the prototypical NF-jB transcription
factor, p65 and p50, form a heterodimer that remains
inactive in the cytoplasm in association with its inhibitor,
IjB. The phosphorylation, dissociation, and proteolysis of
IjB are mediated by the IjB kinase (IKK) complex, which
contains two catalytic subunits, IKKa/IKK1 and IKKb/
IKK2, and a regulatory subunit IKKc/NEMO (NF-jB
essential modulator). Upon release of IjB, NF-jB is free to
translocate from cytoplasm to the nucleus to regulate the
expression of its target genes (Granville et al. 2000; Le-
nardo and Baltimore 1989; Li and Verma 2002). Besides its
role in carcinogenesis, NF-jB is shown to prevent apop-
tosis in transformed cells and enhance survival in many
types of cancers (Baldwin 2001; Danial and Korsmeyer
2004; Gilmore 2003; Jung et al. 1995; Kataoka et al. 2002;
Kucharczak et al. 2003; Tang et al. 2001). Not surprisingly,
accumulating evidence indicates that NF-jB and its con-
trolled pro-survival elements play an essential function in
the response of cells to low or high doses of IR (Ahmed
et al. 2009; Brach et al. 1991; Luo et al. 2005). Recent data
demonstrate that IR can activate NF-jB through an atypi-
cal/non-canonical pathway that is initiated in the nucleus
via ATM-mediated SUMO (small ubiquitin-like modifier)
pathway that involves the sumoylation of NEMO in the
cytoplasm, which then results in its nuclear translocation
and subsequent association with ATM in the nucleus.
ATM-dependent phosphorylation causes the nuclear export
of NEMO and activation of the typical pathway (Curry
et al. 1999). This is an important finding that established
the mechanism of the activation of cytoplasmic stress
sensors like NF-jB by DNA damage signals that are pre-
dominant in the nucleus of an irradiated cell.
Many studies, some still ongoing, investigate the effects
of the inhibition of NF-jB activity in the radiation
response. Inhibition of NF-jB has been shown to modulate
ATM-associated apoptosis (Jung and Dritschilo 2001; Jung
et al. 1997) and notably to enhance heat-mediated radio-
sensitization (Curry et al. 1999; Locke et al. 2002). How-
ever, blocking NF-jB activity has been shown to result in a
variant degree of sensitization of tumor cells to therapeutic
radiation. This inconsistency highly likely stems from the
ability of NF-jB to regulate many different effector genes
involved in a wide array of physiological functions,
sometimes even causing opposite effects (Barkett and
Gilmore 1999; Romashkova and Makarov 1999). There-
fore, it is crucial to further identify and therapeutically
target the specific NF-jB effector genes that mediate the
survival response upon IR, especially those functioning in
tumor-acquired radioresistance and/or radiation-resistant
cancer stem cells. NF-jB signaling network was shown to
be activated in breast CSCs (Diehn et al. 2009). Our studies
demonstrated that NF-jB can be activated via HER2
overexpression, and active NF-jB, subsequently, causes
increased overexpression of HER2 in breast cancer cells
with the radioresistant phenotype (Cao et al. 2009). This
study indicated the existence of an elegant survival strategy
used specifically by breast CSCs. Our results support the
hypothesis that HER2-NF-jB-HER2 loop is specifically
activated as a survival mechanism in the breast CSCs upon
radiation treatment, which may confer radioresistance to
CSCs and will be discussed in details below.
Overexpression of HER-2 in breast cancer and therapy
resistance
In clinic, HER2 is overexpressed in 25–30 % of the total
breast cancer patients (Haffty et al. 1996; Valabrega et al.
2007). HER2 overexpression is found to be associated with
aggressive tumor growth, resistance to treatment, metas-
tasis, and a high risk of local relapse and recurrence
resulting in poor prognosis (Haffty et al. 1996; Holbro et al.
2003; Slamon et al. 1987). HER2, which is linked to
BCSCs (Diehn et al. 2009), was found to be a crucial
biomarker for many types of cancer based on its expression
levels despite a lack of gene mutation or truncation of the
protein (Warren and Landgraf 2006). Furthermore, HER2
expression level is being used as a predictive marker for the
diagnosis of metastatic breast cancer and is an important
factor for designing a treatment plan (Haffty et al. 1996;
Hicks et al. 2005).
HER2 is a proto-oncogene located in the long arm of
human chromosome 17 and encodes a 185 kD transmem-
brane glycoprotein in tissues of epithelial, mesenchymal,
and neural origin (Olayioye 2001; Soomro et al. 1991).
HER2 belongs to the ErbB family of receptor tyrosine
kinases, which comprises four members: EGFR (ErB1/
HER1), ErbB2/HER2/Neu, ErbB3/HER3, and ErbB4/
HER4 (Citri and Yarden 2006). Signal transduction from
these receptors is initiated by ligand binding to the extra-
cellular domain of the receptor followed by receptor
dimerization and trans-autophosphorylation of specific
tyrosine residues within the receptor’s cytoplasmic domain.
The phosphorylated active receptor then recruits down-
stream signaling proteins containing Src homology 2 (SH2)
and phosphotyrosine binding (PTB) domains with a high
affinity for phosphotyrosine residues. The binding of these
specific effector proteins to the activated receptor leads to
the activation of many different signaling pathways
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including Ras-MAPK, phosphatidylinositol 3’kinase-protein
kinase B (PI3K-PKB/Akt), and phospholipase C–protein
kinase C (PLC-PKC) pathways and enables receptor coupling
to biological responses (Warren and Landgraf 2006).
Although there have not been any soluble ligands identified
for HER2 so far, it plays a crucial role in ErbB signaling via its
strong kinase activity and as the preferred partner of other
ErbB family members (Citri and Yarden 2006; Warren and
Landgraf 2006). Moreover, HER2 can spontaneously form
homodimers and automatically phosphorylate itself to obtain
intrinsic tyrosine kinase activity (Eccles 2001). Not surpris-
ingly, altered ErbB signaling has been involved in cancer
development and progression since it is responsible for reg-
ulating proliferation, survival, and/or differentiation (Britten
2004; Warren and Landgraf 2006).
Studies on ErbB family members and their involvement
in cancer development and progression led scientists to
develop antibodies against some individual members of the
family. The anti-HER2 monoclonal antibody, rhumAb-
HER2 (trastuzumab/Herceptin), is the first of these anti-
cancer agents suppressing HER2 activity (Uno et al. 2001).
It is the humanized form of the murine 4D5 antibody that is
directed to the external domain of HER2 and inhibits the
growth of the cells that are positive in HER2 expression.
FDA approved this anti-HER2 antibody to be used in
treatment for metastatic breast cancers overexpressing
HER2 (Liang et al. 2003b; Slamon et al. 2001). Herceptin,
which has been shown to inhibit proliferation of the breast
cancer cells, also promotes the radiation-induced apoptosis
and radiosensitize the cancer cells depending on their level
of HER2 expression (Liang et al. 2003b). Both primary and
metastatic breast tumors have been shown to have over-
expression of HER2 (Valabrega et al. 2007), suggesting the
potential success of Herceptin as a cure for both primary
and metastatic breast cancer. Clinical trials show, however,
that patients with HER2 protein overexpression (detected
by immunohistochemistry (IHC)) are less likely to respond
to the Herceptin treatment than patients with amplified
HER2 gene copy number detected by fluorescence in situ
hybridization (FISH) (Mass et al. 2005). So far, the only
explanation given for this inconsistency is the different
sensitivities of the IHC and FISH methods in determining
the HER2 protein levels and gene copy numbers, respec-
tively (Press et al. 2002; Valabrega et al. 2007). However,
we propose an alternative explanation to this controversy in
the following section, involving several factors, mainly
HER2 and NF-jB, which have important functions in
major signaling pathways.
HER2 overexpression induces mammary carcinogene-
sis, tumor growth, and invasion affecting normal and
malignant mammary stem cells (Korkaya et al. 2008). The
number of the stem/progenitor cells increases in normal
mammary epithelial cells upon overexpression of HER2.
The mammary cells with enhanced HER2 levels also
increased ALDH1 levels (Diehn et al. 2009). These data
are significant given that ALDH1 is suggested as a CSC
marker for some tumors, including breast cancer (Diehn
et al. 2009; Ginestier et al. 2007).
NF-jB-regulated HER2 gene expression
Data from our laboratory suggested HER2 as a marker for
radioresistant breast CSCs as we have shown that HER2-
expressing breast CSCs are more radioresistant and
aggressive compared to HER2-negative breast CSCs (Cao
et al. 2009; Duru et al. 2012). Thus, HER2-negative cancer
may awake the silenced HER2 expression upon radio-
therapy, and HER2-expressing breast CSCs are enriched in
recurrent breast tumors (Figs. 1 and 2), which explains the
potential clinical benefits of anti-HER2 therapy in origi-
nally HER2-negative breast cancer. Also, overexpression
of HER2/neu in HER2-negative breast cancer cells resulted
in resistance to anti-cancer radiation therapy via the acti-
vation of signaling pathways that involve NF-jB signaling
(Cao et al. 2009). Although exact molecular networks
causing radioadaptive tumor resistance in HER2-negative
tumors are still largely unknown, data in our laboratory
indicated that expression of HER2 is controlled by NF-jB,
which is associated with FIR-induced radioresistance. With
promoter/transcription factor analysis, potential NF-jB
binding site was identified as GGG ACG ACC C (-364 bp
to -355 bp) in HER2 promoter. Further, we found that NF-
jB is recruited to HER2 promoter in vivo after radiation.
When activation of NF-jB is inhibited, promoter activity
of HER2 is also compromised. Importantly, NF-jB-medi-
ated HER2 overexpression was found in FIR-induced
radioresistant breast CSCs, which can be sensitized by a
NF-jB inhibitor (Cao et al. 2009). Therefore, NF-jB-reg-
ulated HER2 signaling is critical for radiation-adaptive
resistance in BCSCs. Finding the mechanisms underlying
the adaptive radioresistance and identifying molecular
markers of breast cancer stem cells holds great promise for
effective cancer therapeutics. Given our recent findings that
HER2-mediated radioresistance of breast cancer is initiated
by radiation via NF-jB activation, blocking the NF-jB/
HER2 network, including many mediators/effectors of the
network, will be a crucial approach for sensitizing resistant
breast cancer cells to radiotherapy.
Activation of HER2-NF-jB-HER2 loop in breast cancer
radioresistance
Overexpression of HER2 not only increases cell prolifer-
ation and survival (Kurokawa and Arteaga 2001), but also
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causes NF-jB activation via PI3 K/Akt pathway (Guo et al.
2004), which can be inhibited by the tumor suppressor
phosphatase PTEN (Pianetti et al. 2001). Our laboratory
previously reported that NF-jB and its regulated genes are
activated by HER2 overexpression (Guo et al. 2004), and
HER2-overexpressing MCF7/HER2 cells show enhanced
resistance to IR-induced apoptosis with increased post-
radiation clonogenic survival (Liang et al. 2003b; Pietras
et al. 1999), while stable transfection of mutant IjB
(MCF7/HER2/mIjB) or treatment with Herceptin inhibits
NF-jB activation and radiosensitize them (Guo et al.
2004). We also found that Akt is required for HER2-
mediated NF-jB activation in radiation response (Guo
et al. 2004). Further studies showed that MAPK and PI3K/
Akt pathways are involved in HER2-mediated resistance to
radiation-induced apoptosis in breast cancer cells (Liang
et al. 2003a), especially in HER2-expressing cells (Yang
et al. 2000). Taken together, it is clear that NF-jB and
HER2 are mutually dependent in signaling breast cancer
radioresistance.
Breast cancer MCF7 cells that do not express a high
level of HER2 can induce HER2 expression with adaptive
radioresistance after exposure to fractionated high dose
radiation (Guo et al. 2003; Li et al. 2001). Accumulating
data suggest that there is a unique radioadaptive signaling
pathway linked with induction of multidrug resistance-
associated protein (MRP) (Harvie et al. 1997) and EGFR
(Schmidt-Ullrich et al. 1997) in breast cancer cells. How-
ever, it has been recently shown that HER2 gene is also
sensitive to radiation and can be induced by IR in breast
cancer cell lines. IR-induced NF-jB mediates HER2
overexpression in the radioresistant breast cancer cells
selected from FIR-derived heterogenic population (Cao
et al. 2009), indicating that not only HER2 can induce NF-
Breast cancer cells with HER2+/CD44 +/CD24 -/low cancer stem cell feature





Fig. 1 Schematic representation of HER2?/CD44?/CD24-/low, a
new feature of breast cancer stem cells in tumor resistance to
radiation. The radiation therapy applied to the established tumor
composing from heterogeneous cell lines cause tumor regression.
Breast cancer stem cells with CD44?/CD24-/low marker and HER2
overexpression would be resistant to radiation therapy by activating
HER2-NF-jB-HER2 signaling loop. The overexpression of both
HER2 and NF-jB might change the gene profile of the cells with
HER?/CD44?/CD24-/low feature causing an increase in the number
of genes responsible for proliferation, homing, and invasion. Thus, the
initial regression in the tumor seen after radiation therapy would be
because of the death of the cells without HER?/CD44?/CD24-/low
feature lacking activated HER2-NF-jB-HER2 loop. The selected
cells with the HER?/CD44?/CD24-/low feature, having stem cell-like
properties, would self-renew and also give rise to the other cell types,
making the tumor more aggressive and invasive
Fig. 2 The comparison of the detection methods for confirming
HER2 status of breast tumors. Several clinical trials show the
discrepancy between the results obtained via FISH and IHC (adapted
from Duru et al. 2012)
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jB activity upon IR but also NF-jB can induce the over-
expression of HER2. These results suggest a loop-like
pathway of HER2-NF-jB-HER2 in tumor-adaptive radio-
resistance (Fig. 1). Our recent data support the hypothesis
that HER2-NF-jB-HER2 loop is specifically conjugated
with CD44?/CD24-/low markers of breast CSCs (Duru
et al. 2012). Identification of such positive loop of breast
cancer radioresistance mediators may reveal the overly
aggressive approach the cancer cells may take to achieve
therapy resistance.
Conclusion and perspective
In light of accumulating evidence of the features of CSCs
in human cancer, the original BCSC biomarkers including
CD44?/CD24-/low should be revised to represent the
increase in pro-invasiveness and aggressiveness since these
two markers alone are not found to be sufficient for
metastasis (Sheridan et al. 2006). The HER2-NF-jB-HER2
loop detected in radiation-treated breast cancer cells
suggests that NF-jB and HER2 mediate each other’s
expression (Cao et al. 2009), which is activated by anti-
cancer therapy and thus a potential therapeutic target to
sensitize breast cancer.
Another layer of tumor resistance is linked with the
now-generally-acceptable cancer stem cell theory that
tumor is a highly heterogeneous cell population. Both
CSCs and non-CSCs are present where the population of
the non-CSCs is higher than that of the CSCs, and the
sensitivity of non-CSCs within the tumor is responsible for
the initial tumor regression seen after radiation therapy.
The CSCs are not killed because they activate the HER2-
NF-jB-HER2 loop and, therefore, have selective advan-
tage over non-CSCs against radiation (Fig. 1) (Duru et al.
2012). This hypothesis is supported by the clinical data,
which show that breast cancer patients with recurrent
invasive tumors are HER2-positive; however, the gene
copy number of HER2 detected with FISH in the same
patients is not elevated compared to the primary tumors
(Cao et al. 2009). Several clinical trials show the discrep-
ancy between the results obtained from FISH and IHC
Fig. 3 Schematic presentation of potential signaling network of
HER2-NF-jB-PI3 K-Akt-STAT3. This signaling pathway is assumed
based on the current literature, which, we believe, is activated by
cellular adaptive response under anti-cancer chemo- and/or radio-
therapy, and contributes to an adaptive resistance in cancer cells. Note
that, the HER2-NF-jB-PI3 K-Akt-STAT3 pathway proposed here
may be activated not only in the HER2-positive breast cancer but also
activated in the HER2-negative cancer since HER2 transcription is
shown to be induced by radiation and DNA-damaging anti-cancer
modalities without HER2 gene copy enhancement
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(Fig. 2). We have shown that the breast cancer cells, which
are either missing HER2 or have low HER2 expression
before radiation therapy, may present a radioresistant
phenotype after the treatment due to the increased
expression of HER2 and/or the HER2-NF-jB-HER2 loop
activation following IR. These data are promising and
important as they offer HER2 protein levels but not the
HER2 gene copy number as a marker for breast cancer
recurrence and radioresistance. These data are also crucial
since they suggest that HER2 levels in the breast cancer
patients should be closely monitored during the course of
the treatment as HER2 expression might drastically
increase as the therapy progresses. Further clinical studies
are in need to verify that HER2 protein (detectable by IHC)
as well as HER2 gene copy number is a dynamic feature in
cancer cells and responsible for recurrent or metastatic
tumors.
Further exploring the insight into HER2 network is also
necessary. For instance, signal transducer and activator of
transcription 3 (STAT3) in the HER2, NF-jB, PI3K/Akt
network is promising since STAT3 emerges as another key
player with an important role in HER2 positive breast
CSCs (Fig. 3). HER2 is known to activate STAT3 through
both JAK2- and Src-dependent manners (Ren and Schaefer
2002), and STAT3, in turn, promotes chemoresistance in
head and neck cancer cells (Bourguignon et al. 2012).
HER2-STAT3 signaling network is linked with the
aggressiveness of HER2-expressing breast CSCs (Duru
et al. 2012). Therefore, STAT3 may be the key factors
downstream of HER2 activation (Korkaya et al. 2012).
Moreover, it is known that STAT3 activates NF-jB, and its
downstream targets Lin28 and let7 (Korkaya et al. 2011).
Interestingly, in a recent paper, Lin28 expression was
shown to be significantly associated with HER2 expression
emphasizing that both proteins are associated with a poor
clinical outcome for breast cancer (Feng et al. 2012). Lin28
can regulate HER2 such that Lin28 and HER2, two
important stem cell regulatory genes, may act in a positive
feedback loop (Malik et al. 2012). Therefore, investigation
of the HER2-STAT3 signaling network and other HER2-
linked effectors/pathways may provide more informative
data on tumor adaptive resistance and effective targets to
treat the aggressive recurrent and metastatic lesions.
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